Linker Information

General Information of This Linker
Linker ID
LIN0BCHZT
Linker Name
DBM linker
Linker Type
Cathepsin-cleavable linker
Antibody-Linker Relation
Cleavable
Structure
Formula
C11H14BrNO4
Isosmiles
O=C(N1CCCCCC(O)=O)C(Br)=C(C)C1=O
PubChem CID
170365761
InChI
InChI=1S/C11H14BrNO4/c1-7-9(12)11(17)13(10(7)16)6-4-2-3-5-8(14)15/h2-6H2,1H3,(H,14,15)
InChIKey
NGNNOQRMXMJJDO-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
304.14
Polar area
74.68
Complexity
341.4995491
xlogp Value
1.6691
Heavy Count
17
Rot Bonds
6
Hbond acc
3
Hbond Donor
1
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
C1.18 DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
146C: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
58.62 nM
High C10orf54 expression (C10orf54 +++)
Method Description
146C: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
146C: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 146C: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
164A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.3 nM
High C10orf54 expression (C10orf54 +++)
Method Description
164A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
62.86 nM
High C10orf54 expression (C10orf54 +++)
Method Description
164A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 164A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
208A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.31 nM
High C10orf54 expression (C10orf54 +++)
Method Description
208A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
208A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 208A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
215A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.43 nM
High C10orf54 expression (C10orf54 +++)
Method Description
215A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
215A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 215A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
230A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
3.06 nM
High C10orf54 expression (C10orf54 +++)
Method Description
230A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
230A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 230A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
259A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
1.56 nM
High C10orf54 expression (C10orf54 +++)
Method Description
259A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
259A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 259A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
305A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.81 nM
High C10orf54 expression (C10orf54 +++)
Method Description
305A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
305A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 305A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
353A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.51 nM
High C10orf54 expression (C10orf54 +++)
Method Description
353A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
353A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 53A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
5B: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
1.01 nM
High C10orf54 expression (C10orf54 +++)
Method Description
5B: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 100 nM High C10orf54 expression (C10orf54 +++)
Method Description
5B: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 5B: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) < 0.001 nM High C10orf54 expression (C10orf54 +++)
Method Description
175A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.16 nM
High C10orf54 expression (C10orf54 +++)
Method Description
175A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
7.83 nM
High C10orf54 expression (C10orf54 +++)
Method Description
175A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 175A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.02 nM
High C10orf54 expression (C10orf54 +++)
Method Description
76E1: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.08 nM
High C10orf54 expression (C10orf54 +++)
Method Description
76E1: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.11 nM
High C10orf54 expression (C10orf54 +++)
Method Description
76E1: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 353A: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.16 nM
High C10orf54 expression (C10orf54 +++)
Method Description
53A: DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model Acute myeloid leukemia, Childhood acute myeloid leukemia P31/FUJ cells CVCL_1632
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.34 nM
High C10orf54 expression (C10orf54 +++)
Method Description
53A: DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia OCI/AML3 cells CVCL_1844
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
4.97 nM
High C10orf54 expression (C10orf54 +++)
Method Description
53A: DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model Acute promyelocytic leukemia PL21 cells CVCL_2161
CN114230664B 76E1: DBM- (C6)-MMAF [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.06 nM
High Nectin-4 expression (Nectin-4 +++)
Method Description
NEC49-9-A was tested in MDA-MB-468,1×106/ml,1h
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.07 nM
High Nectin-4 expression (Nectin-4 +++)
Method Description
NEC49-9-A was tested in T47D,1×106/ml,1h
In Vitro Model Invasive breast carcinoma of no special type T47D cells CVCL_0553
Experiment 3 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.78 nM
High Nectin-4 expression (Nectin-4 +++)
Method Description
NEC49-9-A was tested in Nectin4-CHOK1,1×106/ml,1h
In Vitro Model Normal CHOK1 cells CVCL_0214
References
Ref 1 Anti-C10orf54 antibodies and uses thereof
Ref 2 Pharmaceutical compositions comprising anti-Nectin-4 antibody-drug conjugates and uses thereof